N-(4-クロロフェニル)-1-(3-(2-フリル)ベンゾイル)ピペリジン-3-カルボアミド

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P501：内容物/容器を．．．に廃棄すること。

N-(4-クロロフェニル)-1-(3-(2-フリル)ベンゾイル)ピペリジン-3-カルボアミド 価格

N-(4-クロロフェニル)-1-(3-(2-フリル)ベンゾイル)ピペリジン-3-カルボアミド 化学特性,用途語,生産方法

• 使用

  CCG 203971 acts as an antifibrotic agent, inhibiting fibrosis through targeting the MRTF/SRF gene transcription pathway. Inhibits the invasion of prostate cancer cells and acts as a potent anti-proliferative agent.

• Biochem/physiol Actions

  CCG-203971 is an inhibitor of the Rho/MKL1/SRF transcriptional pathway, which has been shown to play a role in metastasis of melanoma and breast cancer and clinically associated with castration-resistant prostate cancer. CCG-203971 is a second-generation analog of CCG-1423 (SML0987) with an IC50 of 4.2 μM vs 1 μM for CCG-1423, but less cytotoxicity. In mouse studies, CCG-203971 inhibited invasion of PC-3 prostate cancer cells and was well tolerated up to doses of 100 mg/kg IP over 5 days. The Rho/MRTF/SRF pathway has also been shown to be involved in multiple types of solid organ fibrosis. CCG-203971 repressed both matrix-stiffness and TGF-β-mediated fibrogenesis in human colonic myofibroblasts and showed antifibrotic activity in a murine model of skin injury and in pulmonary fibrosis lung fibroblasts.

N-(4-クロロフェニル)-1-(3-(2-フリル)ベンゾイル)ピペリジン-3-カルボアミド 生産企業

Global(79)Suppliers